Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-127139
Filing Date
2024-11-14
Accepted
2024-11-14 16:45:24
Documents
71
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vcnx-20240930.htm   iXBRL 10-Q 1928024
2 EX-31.1 vcnx-ex31_1.htm EX-31.1 22413
3 EX-31.2 vcnx-ex31_2.htm EX-31.2 22380
4 EX-32.1 vcnx-ex32_1.htm EX-32.1 11880
  Complete submission text file 0000950170-24-127139.txt   8561233

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vcnx-20240930.xsd EX-101.SCH 1365364
74 EXTRACTED XBRL INSTANCE DOCUMENT vcnx-20240930_htm.xml XML 1367583
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

IRS No.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38624 | Film No.: 241463644
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)